MBX Biosciences, Inc. Common Stock (MBX)
Pre-earnings consensus targets and post-earnings beat/miss — standardized metrics from the earnings calendar. No narrative, no price targets.
Pre-earnings
Consensus targets for the next print, plus how the business has been running.
Next report
Nov 5, 2026
Consensus estimate row
EPS target
$-0.76
Street estimate
Revenue target
—
Street estimate
Trailing EPS (avg 4Q)
$-0.60
Beat rate last 4: 75%
Latest EPS YoY
-34.5%
vs 2025-08-07
Latest revenue YoY
—
How results look so far
Trailing revenue (avg 4Q)
—
Printed quarters
EPS beat rate (4Q)
75%
Share of quarters that beat EPS est.
Post-earnings
Did the company hit the target? Actual vs estimate and surprise.
Last print
Aug 6, 2026
EPS miss
EPS actual / est
$-0.78 / $-0.63
-23.3%
Revenue actual / est
— / —
—
Result
Below target
Based on EPS vs consensus
Earnings history
Estimate vs actual and surprise % by print date
| Date | EPS est | EPS act | EPS surprise | Rev est | Rev act | Rev surprise |
|---|---|---|---|---|---|---|
| 11/5/2026upcoming | $-0.76 | Pending | — | — | Pending | — |
| 8/6/2026 | $-0.63 | $-0.78 | -23.3% | — | Pending | — |
| 5/11/2026upcoming | $-0.60 | Pending | — | — | Pending | — |
| 5/7/2026 | $-0.62 | $-0.51 | +17.7% | — | Pending | — |
| 3/16/2026upcoming | $-0.64 | Pending | — | — | Pending | — |
| 3/12/2026 | $-0.64 | $-0.49 | +23.4% | — | Pending | — |
| 11/6/2025 | $-0.73 | $-0.63 | +13.7% | — | Pending | — |
| 8/7/2025 | $-0.77 | $-0.58 | +24.7% | — | Pending | — |
| 5/12/2025 | $-0.81 | $-0.71 | +12.3% | — | Pending | — |
| 3/17/2025 | $-0.59 | $-0.47 | +20.3% | — | Pending | — |
| 11/7/2024 | $-2.72 | $-2.78 | -2.2% | — | Pending | — |
| 8/23/2024 | — | $-11.47 | — | — | Pending | — |
| 12/31/2023 | — | $-0.26 | — | — | Pending | — |
| 9/30/2023 | — | $-0.32 | — | — | Pending | — |